Trends and outcomes of non-small-cell lung cancer in Omani patients

Experience at a university hospital

Muhammad Furrukh, Shiyam Kumar, Khawaja F. Zahid, Hanan S. Al-Shamly, Zainab A. Al-Jabri, Ikram A. Burney, Mansour S. Al-Moundhri

Research output: Contribution to journalArticle

Abstract

Objectives: The incidence of lung cancer in Oman has shown a gradual but definitive increase since 2002. This study aimed to evaluate the demographic and epidemiological characteristics and survival outcomes of patients with non-small-cell lung cancer (NSCLC) at a university hospital in Oman. Methods: This study was conducted from January to June 2016. A retrospective analysis was performed of consecutive patients diagnosed with NSCLC presenting to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between March 2000 and December 2015. Clinical features at presentation and prognostic and predictive markers were reviewed. Kaplan-Meir estimates were used to determine relapse-free survival, progression-free survival (PFS) and overall survival (OS). Results: A total of 104 patients presented to SQUH during the study period. The median age at diagnosis was 64 years. Overall, 62 patients (59.6%) had adenocarcinomas. Only 12 patients (11.5%) presented in the early stages (I or II) of the disease and the majority of patients had an Eastern Cooperative Oncology Group performance status of 1 (27.9%) or 2 (26.0%). The prevalence of epidermal growth factor receptor mutations was 27.9%. The median PFS for patients with advanced disease (stages III or IV) was five months and the median OS for all patients was seven months. After five years, 50.0%, 60.0%, 10.0% and 8.0% of patients with disease stages I, II, III and IV, respectively, were alive. Conclusion: Patients with NSCLC in Oman were found to present at an advanced stage. However, patient outcomes were similar to those reported in the USA.

Original languageEnglish
Pages (from-to)e301-e308
JournalSultan Qaboos University Medical Journal
Volume17
Issue number3
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Oman
Disease-Free Survival
Survival
Epidermal Growth Factor Receptor
Lung Neoplasms
Adenocarcinoma
Demography
Recurrence
Mutation
Incidence

Keywords

  • Adenocarcinomas
  • Epidermal growth factor receptor
  • Non-small-cell lung carcinomas
  • Oman
  • Patient outcome assessment
  • Survival analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Trends and outcomes of non-small-cell lung cancer in Omani patients : Experience at a university hospital. / Furrukh, Muhammad; Kumar, Shiyam; Zahid, Khawaja F.; Al-Shamly, Hanan S.; Al-Jabri, Zainab A.; Burney, Ikram A.; Al-Moundhri, Mansour S.

In: Sultan Qaboos University Medical Journal, Vol. 17, No. 3, 01.08.2017, p. e301-e308.

Research output: Contribution to journalArticle

@article{de9ab3a44a3a419e95179bdb7dabaaf7,
title = "Trends and outcomes of non-small-cell lung cancer in Omani patients: Experience at a university hospital",
abstract = "Objectives: The incidence of lung cancer in Oman has shown a gradual but definitive increase since 2002. This study aimed to evaluate the demographic and epidemiological characteristics and survival outcomes of patients with non-small-cell lung cancer (NSCLC) at a university hospital in Oman. Methods: This study was conducted from January to June 2016. A retrospective analysis was performed of consecutive patients diagnosed with NSCLC presenting to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between March 2000 and December 2015. Clinical features at presentation and prognostic and predictive markers were reviewed. Kaplan-Meir estimates were used to determine relapse-free survival, progression-free survival (PFS) and overall survival (OS). Results: A total of 104 patients presented to SQUH during the study period. The median age at diagnosis was 64 years. Overall, 62 patients (59.6{\%}) had adenocarcinomas. Only 12 patients (11.5{\%}) presented in the early stages (I or II) of the disease and the majority of patients had an Eastern Cooperative Oncology Group performance status of 1 (27.9{\%}) or 2 (26.0{\%}). The prevalence of epidermal growth factor receptor mutations was 27.9{\%}. The median PFS for patients with advanced disease (stages III or IV) was five months and the median OS for all patients was seven months. After five years, 50.0{\%}, 60.0{\%}, 10.0{\%} and 8.0{\%} of patients with disease stages I, II, III and IV, respectively, were alive. Conclusion: Patients with NSCLC in Oman were found to present at an advanced stage. However, patient outcomes were similar to those reported in the USA.",
keywords = "Adenocarcinomas, Epidermal growth factor receptor, Non-small-cell lung carcinomas, Oman, Patient outcome assessment, Survival analysis",
author = "Muhammad Furrukh and Shiyam Kumar and Zahid, {Khawaja F.} and Al-Shamly, {Hanan S.} and Al-Jabri, {Zainab A.} and Burney, {Ikram A.} and Al-Moundhri, {Mansour S.}",
year = "2017",
month = "8",
day = "1",
doi = "10.18295/squmj.2017.17.03.007",
language = "English",
volume = "17",
pages = "e301--e308",
journal = "Sultan Qaboos University Medical Journal",
issn = "2075-051X",
publisher = "Sultan Qaboos University",
number = "3",

}

TY - JOUR

T1 - Trends and outcomes of non-small-cell lung cancer in Omani patients

T2 - Experience at a university hospital

AU - Furrukh, Muhammad

AU - Kumar, Shiyam

AU - Zahid, Khawaja F.

AU - Al-Shamly, Hanan S.

AU - Al-Jabri, Zainab A.

AU - Burney, Ikram A.

AU - Al-Moundhri, Mansour S.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objectives: The incidence of lung cancer in Oman has shown a gradual but definitive increase since 2002. This study aimed to evaluate the demographic and epidemiological characteristics and survival outcomes of patients with non-small-cell lung cancer (NSCLC) at a university hospital in Oman. Methods: This study was conducted from January to June 2016. A retrospective analysis was performed of consecutive patients diagnosed with NSCLC presenting to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between March 2000 and December 2015. Clinical features at presentation and prognostic and predictive markers were reviewed. Kaplan-Meir estimates were used to determine relapse-free survival, progression-free survival (PFS) and overall survival (OS). Results: A total of 104 patients presented to SQUH during the study period. The median age at diagnosis was 64 years. Overall, 62 patients (59.6%) had adenocarcinomas. Only 12 patients (11.5%) presented in the early stages (I or II) of the disease and the majority of patients had an Eastern Cooperative Oncology Group performance status of 1 (27.9%) or 2 (26.0%). The prevalence of epidermal growth factor receptor mutations was 27.9%. The median PFS for patients with advanced disease (stages III or IV) was five months and the median OS for all patients was seven months. After five years, 50.0%, 60.0%, 10.0% and 8.0% of patients with disease stages I, II, III and IV, respectively, were alive. Conclusion: Patients with NSCLC in Oman were found to present at an advanced stage. However, patient outcomes were similar to those reported in the USA.

AB - Objectives: The incidence of lung cancer in Oman has shown a gradual but definitive increase since 2002. This study aimed to evaluate the demographic and epidemiological characteristics and survival outcomes of patients with non-small-cell lung cancer (NSCLC) at a university hospital in Oman. Methods: This study was conducted from January to June 2016. A retrospective analysis was performed of consecutive patients diagnosed with NSCLC presenting to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between March 2000 and December 2015. Clinical features at presentation and prognostic and predictive markers were reviewed. Kaplan-Meir estimates were used to determine relapse-free survival, progression-free survival (PFS) and overall survival (OS). Results: A total of 104 patients presented to SQUH during the study period. The median age at diagnosis was 64 years. Overall, 62 patients (59.6%) had adenocarcinomas. Only 12 patients (11.5%) presented in the early stages (I or II) of the disease and the majority of patients had an Eastern Cooperative Oncology Group performance status of 1 (27.9%) or 2 (26.0%). The prevalence of epidermal growth factor receptor mutations was 27.9%. The median PFS for patients with advanced disease (stages III or IV) was five months and the median OS for all patients was seven months. After five years, 50.0%, 60.0%, 10.0% and 8.0% of patients with disease stages I, II, III and IV, respectively, were alive. Conclusion: Patients with NSCLC in Oman were found to present at an advanced stage. However, patient outcomes were similar to those reported in the USA.

KW - Adenocarcinomas

KW - Epidermal growth factor receptor

KW - Non-small-cell lung carcinomas

KW - Oman

KW - Patient outcome assessment

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=85031294753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031294753&partnerID=8YFLogxK

U2 - 10.18295/squmj.2017.17.03.007

DO - 10.18295/squmj.2017.17.03.007

M3 - Article

VL - 17

SP - e301-e308

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

SN - 2075-051X

IS - 3

ER -